-
Something wrong with this record ?
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis
F. Bonello, S. Pulini, S. Ballanti, M. Gentile, S. Spada, O. Annibali, P. Omedé, S. Ronconi, C. Cangialosi, L. Podda, A. Palmas, A. Malfitano, G. Rivoli, A. Belotti, F. Ciambelli, ID. Vincelli, AM. Cafro, V. Innao, A. Palumbo, P. Sonneveld, A....
Language English Country Switzerland
Document type Journal Article
NLK
Free Medical Journals
from 2009
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
: We conducted a pooled analysis of two phase III trials, RV-MM-EMN-441 and EMN01, to compare maintenance with lenalidomide-prednisone vs. lenalidomide in newly diagnosed transplant-eligible and -ineligible myeloma patients. Primary endpoints were progression-free survival, progression-free survival 2 and overall survival with both regimens. A secondary aim was to evaluate the impact of duration of maintenance on overall survival and on outcome after relapse. A total of 625 patients (lenalidomide-prednisone arm, n = 315; lenalidomide arm, n = 310) were analyzed. The median follow-up was 58 months. Median progression-free survival (25 vs. 19 months; p = 0.08), progression-free survival 2 (56 vs. 49 months; p = 0.9) and overall survival (73 months vs. NR; p = 0.08) were not significantly different between the two arms. Toxicity profiles of lenalidomide-prednisone and lenalidomide were similar, with the exception of neutropenia that was higher in the lenalidomide arm (grade ≥ 3: 9% vs. 19%, p < 0.001), without an increase in the rate of infections. Overall survival (median NR vs. 49 months, p < 0.001), progression-free survival from relapse (median 35 vs. 24 months, p = 0.004) and overall survival from relapse (median not reached vs. 41 months, p = 0.002) were significantly longer in patients continuing maintenance for ≥2 years. We showed that the addition of prednisone at 25 or 50 mg every other day (eod) to lenalidomide maintenance did not induce any significant advantage.
Department of Haematology Alfred Health Monash University Melbourne VIC 3004 Australia
Department of Hematology Erasmus MC Cancer Institute 3015 GD Rotterdam The Netherlands
Department of Oncology and Hematology Niguarda Ca'Granda Hospital 20162 Milano Italy
Division of Hematology ASST Spedali Civili di Brescia 25123 Brescia Italy
Divisione Ematologia UTMO Azienda Ospedaliera Villa Sofia Cervello 90146 Palermo Italy
Ematologia Azienda Ospedaliero Universitaria Sassari 07100 Sassari Italy
Ematologia con TMO Ospedale Santa Maria della Misericordia 06129 Perugia Italy
Ematologia Ospedale S Francesco 08100 Nuoro ATS Sardegna Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS 47014 Meldola Italy
Sc Ematologia ASST Valle Olona 21052 Busto Arsizio Italy
U O Ematologia Clinica Dipartimento di Ematologia Ospedale Civile Spirito Santo 65124 Pescara Italy
Unit of Hematology Stem Cell Transplantation University Campus Bio Medico 00128 Rome Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044082
- 003
- CZ-PrNML
- 005
- 20200109095510.0
- 007
- ta
- 008
- 200107s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers11111735 $2 doi
- 035 __
- $a (PubMed)31694338
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Bonello, Francesca $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126 Torino, Italy.
- 245 10
- $a Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis / $c F. Bonello, S. Pulini, S. Ballanti, M. Gentile, S. Spada, O. Annibali, P. Omedé, S. Ronconi, C. Cangialosi, L. Podda, A. Palmas, A. Malfitano, G. Rivoli, A. Belotti, F. Ciambelli, ID. Vincelli, AM. Cafro, V. Innao, A. Palumbo, P. Sonneveld, A. Spencer, R. Hájek, M. Boccadoro, F. Gay,
- 520 9_
- $a : We conducted a pooled analysis of two phase III trials, RV-MM-EMN-441 and EMN01, to compare maintenance with lenalidomide-prednisone vs. lenalidomide in newly diagnosed transplant-eligible and -ineligible myeloma patients. Primary endpoints were progression-free survival, progression-free survival 2 and overall survival with both regimens. A secondary aim was to evaluate the impact of duration of maintenance on overall survival and on outcome after relapse. A total of 625 patients (lenalidomide-prednisone arm, n = 315; lenalidomide arm, n = 310) were analyzed. The median follow-up was 58 months. Median progression-free survival (25 vs. 19 months; p = 0.08), progression-free survival 2 (56 vs. 49 months; p = 0.9) and overall survival (73 months vs. NR; p = 0.08) were not significantly different between the two arms. Toxicity profiles of lenalidomide-prednisone and lenalidomide were similar, with the exception of neutropenia that was higher in the lenalidomide arm (grade ≥ 3: 9% vs. 19%, p < 0.001), without an increase in the rate of infections. Overall survival (median NR vs. 49 months, p < 0.001), progression-free survival from relapse (median 35 vs. 24 months, p = 0.004) and overall survival from relapse (median not reached vs. 41 months, p = 0.002) were significantly longer in patients continuing maintenance for ≥2 years. We showed that the addition of prednisone at 25 or 50 mg every other day (eod) to lenalidomide maintenance did not induce any significant advantage.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pulini, Stefano $u U.O. Ematologia Clinica, Dipartimento di Ematologia, Ospedale Civile "Spirito Santo", 65124 Pescara, Italy.
- 700 1_
- $a Ballanti, Stelvio $u Ematologia con TMO, Ospedale Santa Maria della Misericordia, 06129 Perugia, Italy.
- 700 1_
- $a Gentile, Massimo $u UOC di Ematologia, AO Cosenza, 87100 Cosenza, Italy.
- 700 1_
- $a Spada, Stefano $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126 Torino, Italy.
- 700 1_
- $a Annibali, Ombretta $u Unit of Hematology, Stem Cell Transplantation, University Campus Bio Medico, 00128 Rome, Italy.
- 700 1_
- $a Omedé, Paola $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126 Torino, Italy.
- 700 1_
- $a Ronconi, Sonia $u Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
- 700 1_
- $a Cangialosi, Clotilde $u Divisione Ematologia UTMO, Azienda Ospedaliera Villa Sofia Cervello, 90146 Palermo, Italy.
- 700 1_
- $a Podda, Luigi $u Ematologia, Azienda Ospedaliero-Universitaria Sassari, 07100 Sassari, Italy.
- 700 1_
- $a Palmas, Angelo $u Ematologia, Ospedale S. Francesco, 08100 Nuoro, ATS Sardegna, Italy.
- 700 1_
- $a Malfitano, Alessandra $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126 Torino, Italy.
- 700 1_
- $a Rivoli, Giulia $u Haematology Clinic, Department of Internal Medicine (DiMI), University of Genoa, Policlinico San Martino, IRCCS per l'Oncologia, 16132 Genova, Italy.
- 700 1_
- $a Belotti, Angelo $u Division of Hematology-ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
- 700 1_
- $a Ciambelli, Fabrizio $u Sc Ematologia, ASST Valle Olona, 21052 Busto Arsizio, Italy.
- 700 1_
- $a Vincelli, Iolanda Donatella $u Divisione di Ematologia, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, 89124 Reggio Calabria, Italy.
- 700 1_
- $a Cafro, Anna Maria $u Department of Oncology and Hematology, Niguarda Ca'Granda Hospital, 20162 Milano, Italy.
- 700 1_
- $a Innao, Vanessa $u Division of Hematology, Department of Human Pathology and the Adult Developmental, Faculty of Medicine, Messina University, 98122 Messina, Italy.
- 700 1_
- $a Palumbo, Antonio $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126 Torino, Italy.
- 700 1_
- $a Sonneveld, Pieter $u Department of Hematology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
- 700 1_
- $a Spencer, Andrew $u Department of Haematology, Alfred Health-Monash University, Melbourne, VIC 3004, Australia.
- 700 1_
- $a Hájek, Roman $u Department of Haematooncology, University Hospital Ostrava, 70852 Ostrava, Czech Republic. Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic.
- 700 1_
- $a Boccadoro, Mario $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126 Torino, Italy.
- 700 1_
- $a Gay, Francesca $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126 Torino, Italy.
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 11, č. 11 (2019)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31694338 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200107 $b ABA008
- 991 __
- $a 20200109095840 $b ABA008
- 999 __
- $a ind $b bmc $g 1480671 $s 1082752
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 11 $c 11 $e 20191105 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- LZP __
- $a Pubmed-20200107
